Launch of Psychedelics DNA Test Kit Phase 1 clinical trial for DMT progressing as planned Pre-clinical In Vivo work scheduled to start at Israeli CRO Strengthened...
Vancouver, British Columbia–(Newsfile Corp. – May 5, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: “1XU1”) (“Entheon” or the “Company“), a biotechnology company focused...
HaluGen’s DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy Vancouver, British Columbia–(Newsfile Corp. – April 6, 2021) – Entheon Biomedical...
Senior Pharmaceutical & Technology Executive and Current SVP, Chief Information Officer, North America at Kyowa Kirin International plc., Previously of IBM, Schering-Plough, Merck and Gilead Joins...
Completion of research and development phase for HaluGen’s Psychedelics Genetic Test Vancouver, British Columbia–(Newsfile Corp. – February 24, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (FSE:...
Vancouver, British Columbia–(Newsfile Corp. – February 22, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused...
Vancouver, British Columbia–(Newsfile Corp. – February 16, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company...
Vancouver, British Columbia–(Newsfile Corp. – February 4, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTC PINK: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company...
Vancouver, British Columbia–(Newsfile Corp. – February 2, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused...
Vancouver, British Columbia–(Newsfile Corp. – January 19, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTC Pink: ENTBF) (“Entheon” or the “Company“), a biotechnology company...